30843-10-8

Basic information

• Product Name: Pyrazolo[1,5-a]pyridine-3-carboxylic acid, 2-Methyl-, ethyl ester
• Synonyms: Pyrazolo[1,5-a]pyridine-3-carboxylic acid, 2-Methyl-, ethyl ester;ethyl 2-Methylpyrazolo[1,5-a]pyridine-3- carboxylate
• CAS NO: 30843-10-8
• Molecular Formula: C₁₁H₁₂N₂O₂
• Molecular Weight: 204.22518
• Mol File: 30843-10-8.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Density: 1.19±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 1.46±0.30(Predicted)
• CAS DataBase Reference: Pyrazolo[1,5-a]pyridine-3-carboxylic acid, 2-Methyl-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrazolo[1,5-a]pyridine-3-carboxylic acid, 2-Methyl-, ethyl ester(30843-10-8)
• EPA Substance Registry System: Pyrazolo[1,5-a]pyridine-3-carboxylic acid, 2-Methyl-, ethyl ester(30843-10-8)

Safety Data

• Hazardous Substances Data: 30843-10-8(Hazardous Substances Data)

Upstream product

• 4341-76-8 Ethyl 2-butynoate 
• 6295-87-0 N-aminopyridin-1-ium iodide 
• 141-97-9 ethyl acetoacetate 
• 110-86-1 pyridine 

Downstream Products

• 80537-08-2 2-methylpyrazolo<1,5-a>pyridine-3-carboxylic acid 
• 80537-06-0 2-Methyl-pyrazolo[1,5-a]pyridine-3-carboxylic acid [2-(2-hydroxy-ethyl)-phenyl]-amide 
• 1312891-91-0 (E)-3-(4-{[2-(2-methylpyrazolo[1,5-a]pyridin-3-yl)ethylamino]methyl}phenyl)acrylic acid methyl ester 
• 1312891-54-5 (E)-N-hydroxy-3-(4-{[2-(2-methylpyrazolo[1,5-a]pyridin-3-yl)ethylamino]methyl}phenyl)acrylamide 
• 1312891-94-3 (E)-3-[4-({isopropyl-[2-(2-methylpyrazolo[1,5-a]pyridin-3-yl)ethyl]amino}methyl)phenyl]acrylic acid methyl ester 
• 1542710-61-1 N-benzyl-2-{2-methylpyrazolo[1,5-a]pyridin-3-yl}-5,6,7,8-tetrahydroquinazolin-4-amine 

Relevant articles and documents

ANTIBACTERIAL COMPOUNDS

The present invention relates to the following compounds, wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.

Design, Synthesis, and Biological Evaluation of Pyrazolo[1,5-a]pyridine-3-carboxamides as Novel Antitubercular Agents

A series of pyrazolo[1,5-a]pyridine-3-carboxamide derivatives were designed and synthesized as new anti-Mycobacterium tuberculosis (Mtb) agents. The compounds exhibit promising in vitro potency with nanomolar MIC values against the drug susceptive H37Rv s

Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors

Histone deacetylase (HDAC) inhibitors have shown promise in treating various forms of cancer. However, many HDAC inhibitors from diverse structural classes have been associated with QT prolongation in humans. Inhibition of the human ether a-go-go related gene (hERG) channel has been associated with QT prolongation and fatal arrhythmias. To determine if the observed cardiac effects of HDAC inhibitors in humans is due to hERG blockade, a highly potent HDAC inhibitor devoid of hERG activity was required. Starting with dacinostat (LAQ824), a highly potent HDAC inhibitor, we explored the SAR to determine the pharmacophores required for HDAC and hERG inhibition. We disclose here the results of these efforts where a high degree of pharmacophore homology between these two targets was discovered. This similarity prevented traditional strategies for mitigating hERG binding/modulation from being successful and novel approaches for reducing hERG inhibition were required. Using a hERG homology model, two compounds, 11r and 25i, were discovered to be highly efficacious with weak affinity for the hERG and other ion channels.